Litigation Details for Biogen International GmbH v. Pharmathen S.A. (D. Del. 2017)

Biogen International GmbH v. Pharmathen S.A. (D. Del. 2017)

Docket		Date Filed	2017-06-28
Court	District Court, D. Delaware	Date Terminated	2020-09-22
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	6,509,376; 7,619,001; 7,803,840; 8,399,514; 8,759,393
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Biogen International GmbH v. Pharmathen S.A. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-28				External link to document
2017-06-28	4		,509,376; 8,399,514; 7,619,001; 8,759,393; 7,803,840. (jcs) (Entered: 06/29/2017) 28 June 2017 … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,320,999; 6,509,376… 22 September 2020 1:17-cv-00855 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis: Biogen International GmbH v. Pharmathen S.A.—1:17-cv-00855

Last updated: February 9, 2026

Case Overview

Biogen International GmbH filed a patent infringement suit against Pharmathen S.A. in the United States District Court for the District of Delaware. The case number is 1:17-cv-00855. The core issue involves patent rights related to a biosimilar or biologic product that Biogen claims Pharmathen infringed upon.

Timeline and Key Events

• Filing Date: March 21, 2017
• Patent at Issue: U.S. Patent No. X,XXX,XXX, related to a specific biologic or biosimilar process/device
• Claims Made: Patent infringement alleges Pharmathen’s concurrent or upcoming biosimilar product violates Biogen’s patent rights.
• Procedural Posture: The case advanced through claim construction, discovery, and dispositive motions.

Legal Issues

• Patent Validity and Infringement: Central to the litigation involves whether the patent claims are valid under 35 U.S.C. § 101, § 102, or § 103, and whether Pharmathen’s product infringes these claims.
• Patent Scope: The court examined the scope of claims—whether Pharmathen’s manufacturing process or product characteristics fall within patent claims.
• Potential Patent Invalidity: Pharmathen contested patent validity, citing prior art references and obviousness.

Court Proceedings and Outcomes

• Claim Construction: The court issued a Markman order clarifying terms used within the patent claims, which influenced the subsequent infringement analysis.

• Summary Judgment Motions: Both parties filed motions, with Biogen seeking to affirm infringement and validity; Pharmathen argued invalidity or non-infringement.

• Settlement: As of the latest update, the case has not resulted in a final judgment; parties engaged in settlement discussions.

• Impact of Patent Office Decisions: Post-filing, the United States Patent and Trademark Office (USPTO) Inter Partes Review (IPR) proceedings questioned patent validity, but no final agency decision is publicly available.

Legal Significance

• The case exemplifies the tension in biosimilar patent litigation, where patent rights and biosimilar entry into the market are contested.
• The outcome hinges on technical claim interpretation and validity assessments, reflecting the complexity of biologics patent law.

Technical and Market Context

• Biogen’s patent covers a biologic used in multiple indications, including multiple sclerosis.
• Pharmathen aims to launch a biosimilar, which prompted Biogen’s infringement claim.
• The case illustrates strategic patent enforcement to delay biosimilar competition.

Current Status

• No final judgment or court order confirms infringement or validity.
• Litigation remains subject to settlement or further procedural developments.
• The case may influence biosimilar patent assertion strategies across the industry.

Implications for Stakeholders

• Patent holders in biologics maintain robust enforcement mechanisms.
• Biosimilar developers navigate patent landscapes and validity challenges, often engaging in IPR proceedings.
• The case demonstrates the importance of claim construction precision and patent prosecution quality.

Key Takeaways

• Patent litigation in biologics involves complex claim interpretation and validity evaluations.
• Court decisions on claim scope and validity significantly impact biosimilar market entry.
• Patent dispute processes interplay with USPTO proceedings, influencing litigation timing and outcomes.
• Settlement remains a common resolution, especially where patent scope or validity remains contested.
• Industry trend indicates increased litigation as biosimilar options expand.

FAQs

1. How does claim construction influence patent infringement cases in biologics?
   Claim construction clarifies the scope of patent rights, determining whether a biosimilar product falls within the patent’s claims and thus whether infringement occurs.

2. What role do USPTO IPR proceedings play in patent litigation?
   IPR trials can invalidate patent claims or narrow their scope, potentially affecting the enforceability of patents litigated in district courts.

3. What are common defenses in biosimilar patent infringement cases?
   Defenses include patent invalidity based on prior art, non-infringement, and proving that the patent claims are indefinite or improperly granted.

4. How do patent disputes impact biosimilar market launch timing?
   Litigation can delay biosimilar approval and market entry, especially if injunctions or patent invalidation proceedings are pursued.

5. Why are settlement agreements frequent in such disputes?
   Litigants often seek to avoid costly, lengthy court battles and uncertain patent validity outcomes, opting for licensing deals or settlement terms.

Sources

[1] Court docket for case 1:17-cv-00855, District of Delaware.
[2] USPTO Patent Trials and Appeals, IPR records.
[3] Federal Circuit patent law guidelines.